Prospective trial of OKT3 for early prophylaxis of rejection in immunologic "high risk" renal transplant recipients: long-term results.
Pomer
S
S
Department of Urology, University of Heidelberg, Germany.
Waldherr
R
R
Möhring
K
K
Kempter
F
F
Wiesel
M
M
Weimer
R
R
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use; D011446:Prospective Studies; D012307:Risk Factors; D013997:Time Factors
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D001379:Azathioprine; D011241:Prednisone